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1. Introduction 
Anaemia is a frequent complication associated with stage 5 chronic kidney disease (CKD), 
and is mainly due to insufficient production of erythropoietin by the kidneys. Accumulation 
of uremic toxins, excessive toxic storage of aluminium in the bone marrow (Miyoshi, 2006), 
blood loss (either iatrogenic, from the puncture sites of the vascular access and blood 
sampling, or from other sources, such as the gastrointestinal tract), and premature 
erythrocyte destruction have also been frequently associated with anaemia in stage 5 CKD 
patients (Medina, 1994; Pisoni, 2004). 
The erythrocyte, presenting a limited biosynthesis capacity, suffers and accumulates 
physical and/or chemical changes, which become more pronounced with cell aging, and 
whenever an unusual physical or chemical stress develops (Locatelli, 2004a). Erythrocytes 
are physically stressed during the haemodialysis process, and metabolically stressed by 
the unfavourable plasmatic environment, due to metabolite accumulation, and by the 
high rate of haemoglobin autoxidation, due to the increase in haemoglobin turnover, a 
physiologic compensation mechanism triggered in case of anaemia (Lucchi, 2000; Stoya, 
2002). The erythrocytes are, therefore, continuously challenged to sustain haemoglobin in 
its reduced functional form, as well as to maintain the integrity and deformability of the 
membrane. 
Leukocytosis is essential as the primary host defence, and neutrophils, the major 
leukocyte population of blood in adults, play a primordial role. It is well known that 
neutrophils have mechanisms that are used to destroy invading microorganisms. These 
cells use oxygen-dependent and oxygen-independent microbicidal artillery to destroy and 
remove infectious agents (Witko-Sarsat, 2000). Activated neutrophils also undergo 
degranulation, with the release of several components, namely, proteases and cationic 
proteins (Witko-Sarsat, 2000).  
In this book chapter we review the cross-talk between changes in erythrocyte membrane 
protein composition and the release of neutrophil activation products.  
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2. Erythrocyte membrane protein composition 
Erythrocyte membrane proteins can be classified into three categories, according to their 
functional properties in the membrane struture (An & Mohandas, 2008; Mohandas & 
Gallagher, 2008). The first includes cytoskeletal proteins, as spectrin (ǂ and ǃ chains), 
protein 4.1, and actin; the second includes integral/transmembrane proteins of which the 
representative proteins are band 3 and glycophorins; the third includes anchoring/linker 
proteins, namely, ankyrin (also known as band 2.1) and protein 4.2. The anchoring/linker 
membrane proteins mediate the attachment of cytoskeletal proteins to integral proteins (Fig. 
1) (Lucchi, 2000; Gallagher, 2005; Mohandas & Gallagher, 2008). 
 
Fig. 1. Schematic representation of red blood cell membrane, showing the topographical 
localization of proteins and their interactions. The membrane is a complex structure in 
which a plasma membrane envelope composed of amphiphilic lipid molecules is anchored 
to a two dimensional elastic network of skeletal proteins through tethering sites 
(transmembrane proteins) embedded in the lipid bilayer. Adapted from An & Mohandas, 
2008. 
The cytoskeleton is a 3-dimensional network of proteins that covers the cytoplasmatic 
surface of the erythrocyte membrane and is responsible for its biconcave shape and the 
properties of elasticity and flexibility. It comprises approximately half the membrane 
protein mass and is primarily composed of spectrin, protein 4.2 and actin. Spectrin is the 
major protein of the cytoskeleton, and, therefore, the primary cause of erythrocyte shape, 
integrity and deformability. It is linked to the lipid bilayer, by vertical protein interactions 
with the transmembrane proteins, band 3 and glicophorin A (Lucchi, 2000). In the vertical 
protein interaction of spectrin with band 3 there are also ankyrin (also known as band 2.1) 
and protein 4.2 involved. A normal linkage of spectrin with the other proteins of the 
cytoskeleton assures normal horizontal protein interactions. The vertical and horizontal 
interactions between membrane constituents account for the integrity, strength, and 
deformability of the cell (An & Mohandas, 2008; Mohandas & Gallagher, 2008). Disruption 
of vertical interactions because of membrane protein deficiencies favours membrane 
vesiculation with loss of surface area and development of spherocytic cells, with increasing 
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rigidity of the cell membrane that may lead to premature spleen sequestration and 
destruction (An & Mohandas, 2008).   
3. Neutrophil activation 
Leukocytosis and recruitment of circulating leukocytes into the affected areas are hallmarks 
of inflammation. Leukocytes are chimio-attracted to inflammatory regions and their 
transmigration from blood to the injured tissue is primarily mediated by the expression of 
cell-adhesion molecules in the endothelium, which interact with surface receptors on 
leukocytes (Muller, 1999; Sullivan, 2000). This leukocyte-endothelial  interaction is regulated 
by a cascade of molecular steps that lead to the morphological changes that accompany 
adhesion. At the inflammatory site, leukocytes release their granular content and may exert 
their phagocytic capacities. 
In acute inflammation, the leukocyte infiltration is predominantly of neutrophils, whereas in 
chronic inflammation an infiltration predominantly of macrophages and lymphocytes is 
observed. Leukocyte-endothelial cell interactions are important for leukocyte transmigration 
and trafficking in physiological conditions. There is increasing evidences that changes in 
those leukocyte-endothelial interactions, due to endothelium damage or dysfunction, might 
be implicated in the pathogenesis of diseases, such as inflammatory diseases (Harlan, 1985; 
Ley, 2007). 
Leukocytosis is essential as the primary host defence, and neutrophils, the major leukocyte 
population of blood in adults, play a primordial role. It is well known that neutrophils have 
mechanisms that are used to destroy invading microorganisms. These cells use an 
extraordinary array of oxygen-dependent and oxygen-independent microbicidal weapons to 
destroy and remove infectious agents (Witko-Sarsat, 2000). Oxygen-dependent mechanisms 
involve the production of reactive oxygen species (ROS), which can be microbicidal (Roos, 
2003), and lead to the development of oxidative stress. Oxygen-independent mechanisms 
include chemotaxis, phagocytosis and degranulation. The generation of microbicidal 
oxidants by neutrophils results from the activation of a multiprotein enzyme complex, 
known as the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
which catalyzes the formation of superoxide anion (O2·–). Activated neutrophils also 
undergo degranulation, with the release of several components, namely, proteases (such as 
elastase) and cationic proteins (such as lactoferrin) (Saito, 1993; Brinkmann, 2004).  
Elastase is a member of the chymotrypsin superfamily of serine proteinases, expressed in 
monocytes and mast cells, but mainly expressed by neutrophils, where it is 
compartmentalized in the primary azurophil granules. The intracellular function of this 
enzyme is the degradation of foreign microorganisms that are phagocytosed by the 
neutrophil (Brinkmann, 2004). Elastase can also degrade local extracellular matrix proteins 
(such as elastin), remodel damaged tissue, and facilitate neutrophil migration into or 
through tissues. Moreover, elastase also modulates cytokine expression at epithelial and 
endothelial surfaces, up-regulating the production of cytokines, such as IL-6, IL-8, 
transforming growth factor ǃ (TGF-ǃ) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF); it also promotes the degradation of cytokines, such as IL-1, TNF-ǂ and IL-
2. There is evidence in literature that high levels of elastase are one of the major pathological 
factors in the development of several chronic inflammatory lung conditions (Fitch, 2006).  
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Plasma lactoferrin is predominantly neutrophil derived and its presence in the specific 
granules is often used to identify these types of granules. Lactoferrin is also found in other 
granules, in the tertiary granules, though in lower concentrations (Olofsson, 1977; Baynes 
1986; Halliwell  Gutteridge, 1990; Saito, 1993). Lactoferrin is a multifunctional iron 
glycoprotein, which is known to exert a broad-spectrum primary defence activity against 
bacteria, fungi, protozoa and viruses. It can bind to large amounts of free iron.  The iron-
bound lactoferrin is taken up by activated macrophages, which express specific lactoferrin 
receptors. During inflammation, this contributes to iron deprivation of the erythroid 
precursors, which do not express lactoferrin receptors (Bárány, 2001). Other mechanisms in 
which lactoferrin is implicated include a growth regulatory function in normal cells, 
coagulation, and perhaps cellular adhesion modulation (Levay and Viljoen, 1995). 
In a recent study of our group (Pereira, 2010), we found that stage 5 CKD patients present a 
decreased expression of the CXCR1  neutrophil surface marker, which plays an important 
role in neutrophil migration (Fig. 2); a higher elastase plasma levels was also found, as 
compared to a control group (table 1).  
 
Fig. 2. Decreased expression of the CXCR1 neutrophil surface markers in stage 5 CKD 
patients. A – Control; B – Stage 5 CKD patient. Cells were stained with allophycocyanin 
(APC) conjugated anti-CD11B and phycoerythrin (PE) conjugated anti-CXCR1. 
CXCR1 is a receptor that recognizes CXC chemokines, particularly, the pro-inflammatory 
IL-8 (Pay, 2006; Sherry, 2008).  The decreased expression of this receptor in neutrophil 
surface is associated to the release of components of neutrophil granules and is correlated 
with the need for inotropic support. Recently, it was reported that the levels of the 
neutrophil chemoattractant receptor, CXCR1, is mildly diminished in CKD pediatric 
patients, as a consequence of the end stage renal disease itself, and that the recurrent serial 
bacterial infections they suffered was markedly exacerbated by CXCR1 neutrophil loss 
(Sherry, 2008). This loss of CXCR1 on neutrophils might be due to the uremic state, to 
changes in leukocyte adhesion molecule expression or membrane microvilli and/or to cross-
desensitization of this receptor, due to prior exposure to several unrelated chemoattractants, 
including N-formylated peptides and the complement cleavage product C5a (Sherry, 2008). 
Chronic exposure of circulating inflammatory cells to these mediators may lead to loss of 
chemokine receptor expression and/or function via cross-desensitization. 
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 Controls 
(n=26) 
All patients 
(n=63) 
Hb (g/dL) 13.90 (13.2-15.00) 10.90 (10.30-12.30)* 
White cell counts (x 109/L) 5.78 ± 1.59 6.23 ± 2.10 
Lymphocytes (x 109/L)  2.35 ± 0.75 1.47 ± 0.60* 
Monocytes (x 109/L)  0.25 ± 0.08 0.38 ± 0.16* 
Neutrophils (x 109/L)  3.03 ± 1.02 4.14 ± 1.79* 
Albumin (g/dL) NM 3.8  0.4  
CRP (mg/dL) 1.75 (0.76-4.70) 5.75 (1.90-14.01)* 
Elastase (μg/L) 28.29 (26.03-34.74) 36.11 (29.69-50.65)* 
Elastase/Neutrophil ratio 10.86 (7.44-12.12) 8.91 (7.43-13.78) 
Lactoferrin (μg/L) 236.56 (193.56-295.03) 239.35 (165.64-332.60) 
Lactoferrin/Neutrophil ratio 72.11 (55.52-111.83) 60.32 (42.82-99.45) 
Table 1. Haematological data and neutrophil activation markers, for controls and for stage 5 
CKD patients.* p<0.05, vs controls. NM: not measured. Results are presented as mean ± 
standard deviation or as median (interquartile ranges). Hb: Haemoglobin; CRP: C-reactive 
protein. Adapted from Costa, 2008a.  
The haemodialysis procedure, itself, seems to lead to neutrophil activation (Costa, 2008a). 
By evaluating CKD patients before and after haemodialysis procedure (Costa, 2008b), we 
found a higher haemoglobin concentration and erythrocyte count after haemodialysis (Table 
2). This increase in circulating erythrocytes, has been associated (Dasselaar, 2007) to a  
 
 Stage 5 CKD Patients 
(n=20)  
Before  After  
Hb (g/dL) 12.10 (10.95-12.80)  13.20 (11.15-14.60)* 
White cell counts (x 109/L) 5.86  1.5 1 5.93   2.19 
Neutrophils (x 109/L)  3.82  1.24 3.97  1.77 
Monocytes (x 109/L)  0.24  0.38 0.17  0.12 
Lymphocytes (x 109/L) 1.64  0.69 1.66  0.64 
Elastase (μg/L) 36.16 (29.71-47.13) 51.69 (40.08-71.68)* 
Elastase/Neutrophil ratio 10.66 (7.32-13.54) 14.66 (13.34-18.95)* 
Lactoferrin (μg/L) 198.61 (137.81-216.97) 236.56 (171.28-363.63)* 
Lactoferrin/Neutrophil ratio 48.33 (33.88-64.31) 60.72 (51.81-94.81)* 
CRP (mg/dL) 3.06 (1.39-5.22) 3.53 (1.54-5.56) 
Table 2. Hematological data and neutrophil activation markers for stage 5 CKD patients, 
before and after haemodialysis procedure. *p<0.05, vs before haemodialysis. Results are 
presented as mean ± standard deviation or as median (interquartile ranges). Hb: 
haemoglobin; CRP: C-reactive protein. Adapted from Costa, 2008b.  
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translocation of erythrocytes from the splanchnic circulation (and possibly from the splenic 
circulation) in order to compensate the hypovolemic stress during dialysis ultrafiltration. 
We also found, after haemodialysis, an increase in mean cell hemoglobin concentration and 
a decrease in mean cell volume that could be related to erythrocyte membrane protein loss 
during the hemodialysis procedure (Costa, 2008b). Markers of neutrophil activation were 
also found to be increased after haemodialysis. In fact, a decrease in CXCR1 neutrophil 
expression was observed after the haemodialysis procedure [before haemodialysis: 252.25 ± 
45.14 MFI (mean fluorescence intensity) vs after haemodialysis: 239.71 ± 47.62 MFI; p=0.04], 
as well as an increase in elastase and lactoferrin plasma levels (Table 2). The enhanced 
neutrophil activation state after haemodialysis could result from different mechanisms; 
namely, complement activation, direct interaction with haemodialysis membrane, and from 
the passage into the blood of bacterial fragments, such as LPS, from contaminated dialysate 
through the dialyzer membrane. 
4. Erythrocyte senescence and/or damage 
In stage 5 CKD patients, the erythrocytes are metabolically stressed by the unfavourable 
plasmatic environment, due to metabolite accumulation; by the high rate of haemoglobin 
autoxidation, due to the increase in haemoglobin turnover, a physiologic compensation 
mechanism triggered to compensate anaemia (Lucchi, 2000; Stoya, 2002). The erythrocytes 
will be further stressed during the haemodialysis procedure. Therefore, the erythrocytes are 
continuously challenged to sustain haemoglobin in its reduced functional form and to 
maintain the integrity and deformability of the membrane. 
When haemoglobin is denatured, it links to the cytoplasmic pole of band 3, triggering its 
aggregation and leading to the formation of strictly lipidic portions of the membrane, poorly 
linked to the cytoskeleton. These cells are, probably, more prone to undergo vesiculation 
(loss of poorly linked membrane portions) whenever they have to circulate through the 
haemodialysis membranes or the microvasculature. Vesiculation may, therefore, lead to 
modifications in the erythrocyte membrane of stage 5 CKD patients (Reliene, 2002; Rocha, 
2005).  
Erythrocytes that develop intracellular defects earlier during their life span are removed 
prematurely from circulation (Santos-Silva, 1998; Rocha-Pereira, 2004). The removal of 
senescent or damaged erythrocytes seems to involve the development of a senescent 
neoantigen on the membrane surface, marking the cell for death. This neoantigen is 
immunologically related to band 3 (Kay, 1994). The deterioration of the erythrocyte 
metabolism and/or of its antioxidant defences may lead to the development of oxidative 
stress within the cell, allowing oxidation and linkage of denatured haemoglobin to the 
cytoplasmatic domain of band 3, promoting its aggregation, the binding of natural anti-band 
3 autoantibodies and complement activation, marking the erythrocyte for death. The band 3 
profile [high molecular weight aggregates (HMWAg), band 3 monomer and proteolytic 
fragments (Pfrag)] is used in order to differentiate younger, damaged and/or senescent 
erythrocytes. Older and damaged erythrocytes present with higher HMWAg and lower 
Pfrag. Younger erythrocytes show reduced HMWAg and higher Pfrag (Santos-Silva, 1998). 
Several diseases, known as inflammatory conditions, present an abnormal band 3 profile, 
suggestive of oxidative stress development (Santos-Silva, 1998; Belo, 2002; Rocha-Pereira, 
2004).   
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Leukocyte activation is part of an inflammatory response, and is an important source of ROS 
and proteases, both of which may impose oxidative and proteolytic damages to erythrocyte 
and plasma constituents. Actually, oxidative stress has been reported to occur in stage 5 
CKD patients and has been proposed as a significant factor in haemodialysis-related 
shortened erythrocyte survival.  
In literature, there are few reports about the effect of CKD and haemodialysis procedure in 
erythrocyte membrane protein composition (Matos, 1997; Wu, 1998; Ibrahim, 2002). Studies 
performed in erythrocytes from stage 5 CKD patients, using cuprophane and 
polyacrylonitrile dialysis membranes, showed some changes in the membrane proteins, 
namely, a reduction in spectrin and band 3, and an isolated reduction in band 3, respectively 
(Sevilhano, 1990; Delmas-Beauvieux, 1995). Wu et al (Wu, 1998) and Ibrahim et al (2002) 
showed that stage 5 CKD patients presented a median osmotic fragility higher than the 
controls, and, after the haemodialysis procedure, that osmotic fragility decreased.   
Recently, we reported for the first time, changes in the erythrocyte membrane band 3 profile 
in stage 5 CKD patients. These patients presented a decrease in HMWAg and in 
HMWAg/band 3 monomer ratio (Fig. 3 and table 3). These changes seem to reflect a 
younger erythrocyte population; however, CKD presented also a decrease in Pfrag and in 
Pfrag/band 3 monomer ratio, both suggesting a rise in erythrocyte damage. Thus, it seems 
that the band 3 profile observed in CKD patients is associated both to an increase in younger 
erythrocytes and to an increase in damaged erythrocytes (Costa, 2008c). This study also 
showed that the haemodialysis procedure per se does not lead to an increase in the studied 
markers of erythrocyte damage. Actually, no differences were found after haemodialysis, in 
band 3 profile. 
 
 Controls 
(n=26) 
Stage 5 CKD patients 
(n=63) 
HMWAg (%) 19.90 (15.42-21.12) 15.23 (13.38-19.40)* 
Band 3 monomer (%) 55.28 (53.39-57.41) 61.84 (56.87-64.41)* 
Pfrag (%) 26.29 ± 4.78 22.70 ± 6.01* 
HMWAg/ Band 3 monomer 0.33 ± 0.07 0.27 ± 0.07* 
Pfrag/ Band 3 monomer 0.48 ± 0.11 0.38 ± 0.13* 
* p<0.05 vs controls. HMWAg; high molecular weight aggregates; Pfrag: proteolytic fragments. Results 
are presented as mean ± standard deviation or as median (interquartile ranges). 
Table 3. Band 3 profile for controls and stage 5 CKD patients. 
Some changes in erythrocyte membrane protein composition of stage 5 CKD patients using 
high-flux polysulfone FX-class dialysers of Fresenius, were also observed (Costa, 2008b; 
Costa, 2008d). A decrease in spectrin was the most significant change (table 4). This 
reduction in spectrin may account for a poor linkage of the cytoskeleton to the membrane, 
favoring membrane vesiculation, and, probably, a reduction in the erythrocyte lifespan of  
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Fig. 3. A- Illustration of two band 3 profiles, one presented by a control (C), and the other 
presented by a stage 5 CKD patient (P). B- Examples of densitometer tracing of 
immunoblots for band 3 profile, C- Control; P – stage 5 CKD patient. HMWAg; high 
molecular weight aggregates; Pfrag: proteolytic fragments. 
 Controls 
(n=26) 
CKD stage 5  Patients 
(n=63) 
Spectrin (%) 27.63 (26.41-28.79) 24.27 (19.39-26.13)* 
Ankyrin (%) 6.971.62 6.53 1.90 
Band 3 (%) 38.57  3.99 39.294.03 
Protein 4.1 (%) 7.561.45 7.24 1.49 
Protein 4.2 (%) 5.510.72 5.44 1.44 
Band 5 (%) 6.820.86 6.87 1.03 
Band 6 (%) 5.191.04 6.981.37* 
Band 7 (%) 2.200.65 3.32 1.24* 
Protein 4.1/Spectrin  0.276 ± 0.624 0.330 ± 0.120a) 
Protein 4.1/Band 3 0.192 (0.154–0.227) 0.183 (0.155-0.208) 
Protein 4.2/Band 3 0.149 (0.125-0.162) 0.138 (0.110-0.163) 
Spectrin/Band 3 0.707 (0.649-0.822) 0.569 (0.512 -0.686)* 
Ankyrin/Band 3 0.185 ± 0.585 0.169 ± 0.057 
Spectrin/Ankirin 4.18 ± 1.07 3.77 ± 1.84 
Table 4. Erythrocyte membrane protein profile for controls and stage 5 CKD patients.* 
p<0.05, vs controls. Results are presented as mean ± standard deviation or as median 
(interquartile ranges). HMWAg; high molecular weight aggregates; Pfrag: proteolytic 
fragments. Adapted from Costa, 2008d. 
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these patients (Reliene, 2002).  Significant increases in protein bands 6 and 7 were also 
observed, which may further reflect an altered membrane protein interaction and 
destabilization of membrane structure. This membrane destabilization was further 
strengthened by the significant changes observed for spectrin/band 3 ratio (Costa, 2008b; 
Costa, 2008d). These membrane protein changes may be due to a higher erythrocyte 
metabolic stress and/or to changes resulting from the haemodialysis procedure per se.  
Studying the effect of the haemodialysis procedure on erythrocyte membrane protein 
composition in stage 5 CKD patients, by evaluating membrane protein composition before 
and immediately after haemodialysis procedure (table 5), some trends towards the control 
profile were observed for some of the membrane proteins – band 3, band 6 and band 7; 
spectrin showed an even lower value after haemodialysis, and ankyrin, protein 4.1, protein 
4.2 and band 5 also presented a trend to decrease. Comparing the ratios before and after 
haemodialysis, only the ratio spectrin/band 3 showed a statistically significant value, 
reflecting a vertical membrane protein disturbance. 
 
 Stage 5 CKD patients 
(n=20)  
Before haemodialysis After haemodialysis 
Spectrin (%) 25.58 (24.10-27.07) 24.47 (22.31-26.95)* 
Ankyrin (%) 6.39  1.55 6.23  1.28 
Band 3 (%) 38.10  3.78 41.13  2.44* 
Protein 4.1 (%) 6.48  1.60 6.39  1.69 
Protein 4.2 (%) 4.34  0.99 4.84  1.04 
Band 5 (%) 6.56  0.91 6.71  0.59 
Band 6 (%) 6.46  0.87 6.17  1.15 
Band 7 (%) 2.09  0.43 2.37  0.34 
Protein 4.1/Spectrin  0.243  0.070  0.251  0.081 
Protein 4.1/Band 3 0.170 (0.138-0.206)  0.163 (0.121-0.202) 
Protein 4.2/Band 3 0.114 (0.101-0.133)  0.118 (0.101-0.147) 
Spectrin/Band 3 0.685 (0.626-0.796)  0.647 (0.566-0.689)* 
Ankyrin/Band 3 0.171  0.049  0.152  0.330 
Spectrin/Ankirin 4.48  1.361 4.45  1.49 
* p<0.05, vs before haemodialysis. Results are presented as mean ± standard deviation or as median 
(interquartile ranges). HMWAg; high molecular weight aggregates; Pfrag: proteolytic fragments. 
Adapted from Costa, 2008b. 
Table 5. Erythrocyte membrane protein profile for stage 5 CKD patients, before and 
immediately after haemodialysis procedure. 
Haemodialysis procedure seems to have an important role in the changes observed for 
erythrocyte membrane protein composition; however, their exact origin(s) are not yet fully 
understood. An hypothesis is that the increased plasma levels of elastase found in stage 5 
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CKD patients could induce changes in erythrocyte membrane proteins, leading to a decrease 
in erythrocyte lifespan, and, consequently, to an increase in the degree of the anaemia. This 
hypothesis was tested (Pereira, 2011), by performing some in vitro assays using erythrocytes 
from 18 stage 5 CKD patients (10 responders and 8 non-responders to recombinant human 
erythropoietin therapy) and from 8 healthy controls; erythrocyte suspensions in phosphate 
buffered saline, pH 7.4, were incubated at 37º C, under gentle rotation, in the presence of 
0.03, 0.1 and 0.5 μg/mL of neutrophil elastase. These assays used erythrocytes collected 
before and immediately after the haemodialysis procedure.  
 
Fig. 4. Changes in ankyrin (A), spectrin (B) and band 3 (C) observed for erythrocytes from 
responder stage 5 CKD patients before haemodialysis, when incubated without and with 
elastase; changes in spectrin presented by erythrocytes from non-responder stage 5 CKD 
patients before haemodialysis, when incubated without and with elastase (D). Adapted 
from Pereira, 2011. 
No significant differences were found between the protein composition of the erythrocyte 
membranes from healthy controls and from stage 5 CKD patients, when their erythrocytes, 
collected after the haemodialysis procedure, were incubated without and with different 
elastase concentrations. However, the erythrocytes from stage 5 CKD patients, collected 
before the haemodialysis procedure, showed some susceptibility to elastase; the 
erythrocytes from responders stage 5 CKD patients, incubated with 0.5 μg/mL of elastase 
showed a significant decrease in ankyrin [7.0 (6.5-7.5%) vs 6.0 (5.9-6.5%), p=0.024], and  
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trends towards a decrease in spectrin [25.6 (25.1-26.9%) vs 24.7 (24.4-25.6%), p=0.073) and an 
increase in band 3 [36.6 (34.8-37.6%) vs 39.1 (36.9-39.4%), p=0.077), as compared with 
erythrocytes incubated without elastase. Similar changes were found for the erythrocytes 
incubated with 0.1 μg/mL of elastase. In non-responders stage 5 CKD patients, the 
erythrocytes incubated with 0.1 and 0.5 μg/mL of elastase, showed a significant decrease in 
spectrin [25.5 (24.9-25.9%) and 25.3 (24.8-26.2%), respectively vs 26.4 (26.0-27.3%), p=0.011 for 
both], as compared to erythrocytes incubated without elastase (Fig. 4).  
These findings suggest that the erythrocytes from stage 5 CKD patients, before the 
haemodialysis procedure, are more susceptible to the proteolytic action of elastase upon the 
membrane. Considering that after the haemodialysis procedure the composition of the 
erythrocyte membrane from stage 5 CKD patients did not change, it seems that the more 
susceptible erythrocytes were removed during the haemodialysis procedure. Moreover, the 
release of neutrophil activation products, such as elastase, during haemodialysis may 
contribute to the removal of the more damaged cells, by enhancing membrane protein 
changes. 
5. Other pathologies associated with neutrophil activation and erythrocyte 
damage 
Several physiological (physical exercise, pregnancy) and pathological (hereditary  
spherocytosis, cardiovascular disease, preeclampsia, psoriasis) conditions presenting with 
neutrophilic leukocytosis have been associated to an altered erythrocyte membrane protein 
composition and to other changes reflecting erythrocyte damage. Moreover, they have been 
associated to increased neutrophil activation products, suggesting that leukocyte activation 
may trigger injuries in the neighboring erythrocytes.  
In Hereditary Spherocytosis (HS), mutations in genes encoding for some membrane proteins 
- band 3, spectrin, protein band 4.2 and ankyrin - may result in their partial or inaccurate 
assembly to the membrane. Deficiencies in one or more of those proteins cause a decrease in 
membrane stability that, in turn, leads to loss of membrane surface area through membrane 
vesiculation. By losing membrane vesicles, the cell will become spherocytic and the 
membrane more rigid, triggering the sequestration of cell in the spleen and, therefore, the 
reduction of the erythrocyte lifespan and the development of anemia (Mohandas & 
Gallagher, 2008).  
Two distinct pathways lead to the reduction in membrane surface area: i) deficiencies in 
spectrin, ankyrin, or protein 4.2 reduce the density of the membrane cytoskeleton, causing a 
weaker linkage to the lipid bilayer, favoring the loss of membrane vesicles containing lipids 
and band 3; ii) deficiency in band 3 favors the development of band 3 deficient areas in the 
membrane, with loss of the lipid-stabilizing effect of band 3, and therefore, the release of 
band 3-free microvesicles, from the membrane (Iolascon, 2003; Perrotta, 2008). In a recent 
work by our group (Rocha, 2010), studying 160 HS patients, the analysis of erythrocyte 
membrane protein profile showed that 109 patients presented a primary deficiency in band 
3, 35 patients a primary ankyrin deficiency, 14 patients an isolated deficiency in spectrin and 
2 patients an isolated deficiency in protein 4.2. Furthermore, severe HS patients presented 
with higher neutrophil count and higher levels of TNF-ǂ, IFN-, elastase, lactoferrin and 
ferritin. Our data show HS as a disease linked to enhanced erythropoiesis that is disturbed 
in the more severe forms, to which inflammation, at least in part, seems to contribute.    
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Patients with cardiovascular disease, namely, with recent myocardial infarction (within the 
last 48 h), survivors for at least 3 months of myocardial infarction and hypertensive 
individuals, presented besides a neutrophilic leukocytosis a different band 3 profile, with 
higher values of HMWAg and lower values of band 3 monomer and of Pfrag (Santos-Silva, 
1995). Ischemic stroke patients presented the same altered band 3 profile, associated with 
increased plasma levels of leukocyte activation products - elastase and lactoferrin - when 
compared with controls (Santos-Silva, 1998). 
Band 3 profile in normal pregnancy in the first trimester of pregnancy, when compared with 
healthy controls, presented significantly reduced HMWAg and increased Pfrag. Comparing 
the third with the first trimester, a significant reduction in band 3 and a significant rise in 
Pfrag was also described. These results suggest band 3 profile as a marker of erythrocyte 
changes in normal pregnancy, which are independent of the ‘physiological anemia’ of 
pregnancy. These changes suggest an increase in damaged erythrocytes, but also an increase 
in younger erythrocytes in the maternal circulation. We also found alterations in the 
markers of erythrocyte damage in preeclampsia, in both umbilical cord blood and maternal 
circulation. In preeclamptic pregnancies in the third trimester of gestation, a significantly 
higher level of elastase and a significantly higher elastase to neutrophil ratio was also 
described, suggesting an increased neutrophil activation in these patients (Belo, 2002; Belo, 
2003). 
Psoriasis was also associated with plasma neutrophil activation, showing increased plasma 
levels of elastase and lactoferrin, associated with alterations in band 3 profile (Rocha-Pereira, 
2004).  
6. Conclusions 
Stage 5 CKD is associated with an altered structure of erythrocyte membrane proteins, 
which may be due to the disease itself and/or to the interaction of blood cells with 
haemodialysis membranes. Haemodialysis procedure seems to contribute to a disturbance 
in the erythrocyte membrane protein structure, as showed by the significant reduction in 
spectrin, the most striking change observed.  
 
Fig. 5. In stage 5 CKD patients, the increased plasma levels of elastase can induce changes in 
erythrocyte membrane proteins, leading to a decrease in the erythrocyte lifespan and, 
consequently, to increase the degree of anaemia in these patients.  
Moreover, stage 5 CKD patients under haemodialysis also present higher elastase plasma 
levels, which might reflect the rise in neutrophils and the enhanced inflammatory process 
found in these patients. Haemodialysis procedure seems to be associated with neutrophil 
activation, with subsequent elastase release that seems to induce changes in the erythrocyte 
membrane protein composition, probably contributing to a decrease in the erythrocyte half-
life, and, therefore to the anemia found in stage 5 CKD patients (Fig. 5).  
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